Incidence of extramural venous invasion in colorectal carcinoma as determined at the invasive tumor front and its prognostic impact.


Journal

Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547

Informations de publication

Date de publication:
04 2019
Historique:
received: 17 07 2018
revised: 26 11 2018
accepted: 27 11 2018
pubmed: 21 12 2018
medline: 20 11 2019
entrez: 21 12 2018
Statut: ppublish

Résumé

Extramural venous invasion (EMVI) is prognostic for colorectal cancer; however, veins are only detected partially by normal perpendicular preparation. Therefore, reported findings are conflicting and standardization is required. A total of 239 resection specimens were examined by tangential preparation of the extramural veins at the invasive tumor front. Average follow-up was 39 months. The relationship of EMVI to metachronous hematogenic metastasis (MHM) was evaluated. With this method, a high prevalence of EMVI beginning in stage II is apparent. In stage I, 66% of patients with EMVI developed MHM; in stage II, 25%; and in stage III, 49%. In stage III, the number of tumor-invaded veins is crucial. In the absence of detection of EMVI, MHM occurred in 1 of 29 patients in stage II and in 2 of 13 patients in early stage III. By tangential sectioning at the invasive tumor front, we found a high incidence of EMVI beginning in stage II, which increases with tumor stage. Especially in stages II and III, the correct determination of absent EMVI has a high negative predictive value for MHM. In stage I, EMVI defines a patient group with increased risk for MHM. The quantification of EMVI is an important issue for standardization.

Identifiants

pubmed: 30571994
pii: S0046-8177(18)30486-6
doi: 10.1016/j.humpath.2018.11.031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102-107

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Klaus Dirschmid (K)

Institute of Pathology, LKH Feldkirch, Carinagasse 47, 6807 Feldkirch, Austria.

William Sterlacci (W)

Institute of Pathology, Hospital Bayreuth, Preuschwitzerstrasse 101, 95445 Bayreuth, Germany. Electronic address: william.sterlacci@klinikum-bayreuth.de.

Ewald Wöll (E)

Department of Internal Medicine, St. Vinzenz Hospital Zams, Sanatoriumstrasse 43, 6511 Zams, Austria.

Peter Tschann (P)

Department of Surgery LKH Feldkirch, Carinagasse 47, 6807, Feldkirch, Austria.

Michaela Rhomberg (M)

Institute of Pathology, LKH Feldkirch, Carinagasse 47, 6807 Feldkirch, Austria.

Felix Offner (F)

Institute of Pathology, LKH Feldkirch, Carinagasse 47, 6807 Feldkirch, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH